LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repair
Open Access
- 26 February 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (3), e341
- https://doi.org/10.1002/ctm2.341
Abstract
PARP inhibitors induce DNA lesions, the repair of which are highly dependent on homologous recombination (HR), and preferentially kill HR‐ deficient cancers. However, cancer cells have developed several mechanisms to transform HR and confer drug resistance to PARP inhibition. Therefore, there is a great clinical interest in exploring new therapies that induce HR deficiency (HRD), thereby sensitizing cancer cells to PARP inhibitors. Here, we found that GSK2578215A, a high‐selective and effective leucine‐rich repeat kinase 2 (LRRK2) inhibitor, or LRRK2 depletion suppresses HR preventing the recruitment of RAD51 to DNA damage sites through disruption of the interaction of RAD51 and BRCA2. Moreover, LRRK2 inhibition or depletion increases the susceptibility of ovarian cancer cells to Olaparib in vitro and in vivo. In clinical specimens, LRRK2 high expression is high related with advanced clinical characteristics and poor survival of ovarian cancer patients. All these findings indicate ovarian cancers expressing high levels of LRRK2 are more resistant to treatment potentially through promoting HR. Furthermore, combination treatment with an LRRK2 and PARP inhibitor may be a novel strategy to improve the effectiveness of LRRK2 expression ovarian cancers.Keywords
This publication has 35 references indexed in Scilit:
- New Tools to Study DNA Double-Strand Break Repair Pathway ChoicePLOS ONE, 2013
- Playing the End Game: DNA Double-Strand Break Repair Pathway ChoiceMolecular Cell, 2012
- The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalitiesMolecular Neurodegeneration, 2012
- The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancersNeurology, 2012
- Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break RepairMolecular Cell, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanismsProceedings of the National Academy of Sciences of the United States of America, 2011
- Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localizationBiochemical Journal, 2010
- Family history of melanoma and Parkinson disease riskNeurology, 2009
- Patterns of somatic mutation in human cancer genomesNature, 2007